This property, in turn, is expected to curtail the inflammatory responses associated with impaired redox balance in the dopaminergic pathway in PD [,] However, most gliptins have the limitation of not being able to cross the bloodbrain barrier (BBB), thereby reducing their effectiveness in targeting neurodegenerative processes in PD
JJW is grateful to Rosetrees Trust for their interdisciplinary award
DOI: 10.17245/jdapm.2022.22.2.141
[Related: Tracy Stuckrath's Essential Meetings F&B Checklist ] Why the GLP-1 Wave Matters for Events Research and reporting across foodservice and retail show consistent patterns among people taking GLP-1 medications: They feel full faster and eat smaller portions
In AWARD-1, the once-weekly injectable GLP-1 agonist demonstrated superior glycemic control compared with twice-daily exenatide (Byetta) in type 2 diabetic patients not adequately controlled with full-dose metformin and pioglitazone
Int J Obes (Lond) 49:433451
